Molecule moves through preclinical development in record time

Anacor Pharmaceuticals and MMV extend development agreement for AN3661.

02 Sep 2011

Anacor Pharmaceuticals announced today that MMV has extended the existing development agreement between the two organizations to fund the clinical development of AN3661, a boron-based drug candidate for the treatment of malaria.  

On April 26, 2010, Anacor and MMV entered into a research collaboration to apply Anacor’s boron chemistry to identify new medicines to treat malaria.  On March 17, 2011, the two organizations entered into a development agreement for AN3661, the first candidate arising from the research collaboration to enter into preclinical development.  At that time, MMV agreed to provide funding for the  the preclinical studies. Under the expanded agreement, MMV will provide additional funding to allow completion of  the Phase 1 clinical trials and a human proof-of-concept study in malaria.

“Utilizing our boron chemistry platform and MMV’s disease expertise, we have been able to rapidly progress AN3661 through preclinical studies in preparation for clinical development,” said David Perry, Chief Executive Officer of Anacor Pharmaceuticals.  “More importantly, AN3661 appears to be acting through a novel mechanism of action, having shown potent activity against the Plasmodium falciparum parasites which are known to have resistance to a number of front-line antimalarial drugs.  This orally delivered compound has demonstrated a remarkable safety andefficacy profile in preclinical studies and has the potential to become a novel and effective treatment for malaria, a disease that causes the deaths of up to one million people a year.”

 “We were excited by AN3661 when Anacor presented the original cell biology data, and the strength of the scientific data has improved steadily over the last year,” said Tim Wells, MMV’s Chief Scientific Officer. “Anacor’s commitment to quality and efficiency has meant that working in partnership we have been able to move the molecule through preclinical development in record time.  We are also happy to be working with Anacor on the next generation of molecules from this platform.”